SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+1.14%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.7B
AUM Growth
-$86.8M
(-3.1%)
Cap. Flow
+$24.7M
Cap. Flow
% of AUM
0.91%
Top 10 Holdings %
Top 10 Hldgs %
42.98%
Holding
115
New
16
Increased
19
Reduced
23
Closed
18
Top Buys
| 1 |
Legend Biotech
LEGN
|
$114M |
| 2 |
Immatics
IMTX
|
$36M |
| 3 |
Coca-Cola
KO
|
$34.2M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$32.3M |
| 5 |
Boeing
BA
|
$27.5M |
Top Sells
| 1 |
Apple
AAPL
|
$78.3M |
| 2 |
Arcellx
ACLX
|
$57.6M |
| 3 |
Royalty Pharma
RPRX
|
$52.8M |
| 4 |
AT&T
T
|
$50.3M |
| 5 |
UnitedHealth
UNH
|
$36.2M |
Sector Composition
| 1 | Healthcare | 60.76% |
| 2 | Consumer Discretionary | 9.71% |
| 3 | Technology | 9.58% |
| 4 | Financials | 6.08% |
| 5 | Communication Services | 5.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zura Bio
ZURA
$132M
| $12.2M | 0.41% |
4,860,939
| – | – |
|
52
Monte Rosa Therapeutics
GLUE
$309M
| $10.9M | 0.37% |
1,563,798
-1,095,202
| -41% | -$7.6M |
|
|
MOLN
53
Molecular Partners
MOLN
$139M
| $10.5M | 0.36% |
2,221,494
+1,821,494
| +455% | +$8.65M |
|
54
Walt Disney
DIS
$211B
| $10.5M | 0.36% |
+94,580
| New | +$10.5M |
|
55
Arcus Biosciences
RCUS
$1.24B
| $8.58M | 0.29% |
576,156
-87,447
| -13% | -$1.3M |
|
|
PVLA
56
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $8.57M | 0.29% |
+714,463
| New | +$8.57M |
|
|
BIOA
57
BioAge Labs, Inc. Common Stock
BIOA
$170M
| $8.41M | 0.29% |
1,452,336
-2,664
| -0.2% | -$15.4K |
|
58
scPharmaceuticals
SCPH
$296M
| $6.52M | 0.22% |
1,840,891
-208,118
| -10% | -$737K |
|
59
Sanofi
SNY
$122B
| $6.34M | 0.22% |
131,501
-43,400
| -25% | -$2.09M |
|
60
GE HealthCare
GEHC
$33B
| $5.86M | 0.2% |
75,000
| – | – |
|
61
Exact Sciences
EXAS
$9.33B
| $5.29M | 0.18% |
94,100
| – | – |
|
62
Merck
MRK
$210B
| $5.27M | 0.18% |
+53,000
| New | +$5.27M |
|
63
Kezar Life Sciences
KZR
$28.5M
| $4.82M | 0.16% |
716,759
| – | – |
|
64
PepGen
PEPG
$39M
| $4.45M | 0.15% |
1,174,321
-486,611
| -29% | -$1.84M |
|
65
Thermo Fisher Scientific
TMO
$183B
| $4.11M | 0.14% |
7,900
+640
| +9% | +$333K |
|
66
Abbott
ABT
$230B
| $3.79M | 0.13% |
33,520
| – | – |
|
67
Danaher
DHR
$143B
| $3.12M | 0.11% |
13,600
-2,827
| -17% | -$649K |
|
68
Elanco Animal Health
ELAN
$8.62B
| $3.07M | 0.1% |
253,600
| – | – |
|
69
Cencora
COR
$57.2B
| $2.81M | 0.1% |
12,488
| – | – |
|
70
Intuitive Surgical
ISRG
$158B
| $2.71M | 0.09% |
5,200
| – | – |
|
71
DexCom
DXCM
$30.9B
| $2.46M | 0.08% |
31,680
| – | – |
|
72
Mettler-Toledo International
MTD
$26.1B
| $2.4M | 0.08% |
1,964
| – | – |
|
73
Sarepta Therapeutics
SRPT
$1.98B
| $2.18M | 0.07% |
+17,888
| New | +$2.18M |
|
74
Bristol-Myers Squibb
BMY
$96.7B
| $1.91M | 0.07% |
+33,800
| New | +$1.91M |
|
75
Natera
NTRA
$23B
| $1.6M | 0.05% |
10,100
| – | – |
|